OBJECTIVES:  To identify evidence on the disease and economic burden associated with two major sub-types of Non-Hodgkin’s lymphoma: diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). METHODS:  Searches were conducted in Medline and Embase (Jan 2012–May 2016) and supplemented with review of conference abstracts (2015–2016). Studies of any design reporting on treatment outcomes and resource use associated with DLBCL or FL, with a sample size ≥50 patients, from the United States (US), European Union 5 (EU5), or Japan were eligible for inclusion in this review. RESULTS:  Twenty-five studies (13 focused on DLBCL and 12 on FL) from US and EU5 met inclusion criteria, with sample sizes ranging from 50 to 6,425 patients. Patients included in FL studies were younger (median age 58–66) compared to DLBCL (median age 43–83). Hospitalization was reported in several studies (3 DLBCL and 2 FL) as an outcome, resulting mainly from febrile neutropenia in patients treated with rituximab-based immunotherapy. Hospitalization rates ranged from 14% to 32% for DLBCL and 3%–11% for FL over a median follow-up period of 26.6–57 months; in one study a subset of patients were followed for 11 years. Of evidence on costs, using individual level data from the UK’s Hematological Malignancy Network, one study estimated that the total medical costs were €23,184 for DLBCL curative treatment and €2,125 for palliative management over a period of 5 years. The other used a Markov cost-effectiveness model to examine treatment strategies in DLBCL, finding sub-type based treatment most cost-effective versus R-CHOP with or without lenalidomide. CONCLUSIONS:  There is limited evidence published on the overall disease or economic burden of DLBCL/FL, with most literature focused on hospitalization from adverse events. More comprehensive research is needed to assess the impact of DLBCL/FL on patients and healthcare systems.